Oric Pharmaceuticals, Inc.
corporate_fare Company Profile
Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 18 items for ORIC at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-16, rated 7/10. Across its 18 most recent items scored 7 or higher, the top rating is 8/10, with 12 rated 8 or above. Recent SEC coverage for ORIC spans 10-Q, 8-K, DEF 14A, 424B5.
Recent high-impact activity:
- ORIC 10-Q: $345M Cash to 2H 2028, R&D Up 51%, New Insider Selling Plans
- ORIC Q3: $345M Cash to 2H 2028, Phase 3 Started in Prostate Cancer
- ORIC Posts $345M Cash Runway to 2028 as First Phase 3 Rinzimetostat Trial Begins
- ORIC's Enozertinib Hits 84% ORR, Sets Phase 3 Redwood-1 for 1H 2027
- Enozertinib Hits 84% ORR in 1L EGFR Atypical NSCLC; Phase 3 Set for 1H 2027
Financial Snapshot
Short Interest & Short Volume
4.80 days to coverFINRA reported short interest of 10,730,120 shares in ORIC as of the October 30, 2026 settlement, a 30.4% decrease from the prior period — about 4.8 days to cover at its recent average daily volume. On November 20, 2026, 32.7% of ORIC volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.